Antigenics Expands Phase II Glioma Trial

28 June 2009 (Last Updated June 28th, 2009 18:30)

Antigenics has announced that the Brain Tumor Research Center at the University of California (UCSF) has expanded Phase II clinical trials of Oncophage (vitespen) for glioma to an additional medical centre. The trial to evaluate overall survival, time to progression and immune response

Antigenics has announced that the Brain Tumor Research Center at the University of California (UCSF) has expanded Phase II clinical trials of Oncophage (vitespen) for glioma to an additional medical centre.

The trial to evaluate overall survival, time to progression and immune response in patients diagnosed with first recurrence of high-grade glioma will now include the New York-Presbyterian Hospital/Columbia University Medical Center.

Data from the Phase II study showed that following brain cancer surgery, the Oncophage vaccination increased overall median survival to approximately 10.5 months, with four patients surviving beyond 12 months and one patient surviving almost 2.5 years.

This is compared to a historical median survival of only 6.5 months post surgery.

All patients enrolled into the trial had at least one recurrence of brain cancer.

UCSF Associate Professor of neurological surgery Andrew Parsa said that the study results were encouraging.

"In this patient population, treatment with Oncophage extended overall median survival to approximately 10.5 months, with a favourable side-effect profile," Parsa said.

The Phase II trial is designed to recruit around 30 patients diagnosed with first recurrence of high-grade glioma and evaluate overall survival, time to progression and immune response.